Which heparin and how much?

Current Cardiology Reports

Volumn 10, Issue 4, 2008, Pages 312-318

  Ruchin, Peter E ^a   Labinaz, Marino ^a  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DALTEPARIN; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; REVIPARIN; THIENOPYRIDINE DERIVATIVE; FIBRINOLYTIC AGENT; POLYSACCHARIDE;

ACUTE CORONARY SYNDROME; ADJUVANT THERAPY; ANTICOAGULATION; BLEEDING; BLOOD BRAIN BARRIER; BRAIN HEMORRHAGE; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY RECANALIZATION; COST BENEFIT ANALYSIS; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EXCRETION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TRANSFORMATION; DRUG TRANSPORT; DRUG WITHDRAWAL; HEART CATHETERIZATION; HEART INFARCTION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INTRACARDIAC THROMBOSIS; LOADING DRUG DOSE; LONG TERM CARE; PERCUTANEOUS CORONARY INTERVENTION; RECOMMENDED DRUG DOSE; REVIEW; RISK BENEFIT ANALYSIS; ST SEGMENT ELEVATION; SYMPTOM; ARTICLE; RISK ASSESSMENT; RISK FACTOR; TRANSLUMINAL CORONARY ANGIOPLASTY;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; FIBRINOLYTIC AGENTS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PLATELET AGGREGATION INHIBITORS; POLYSACCHARIDES; RISK ASSESSMENT; RISK FACTORS;

EID: 54449090720     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-008-0050-0     Document Type: Review

References (42)

1. MIMS Point of Care database, CMP Medica Australia 2007: Heparin sodium injection. http://proxy8.use.hcn.com.au/ifmx-nsapi/mims-data/?MIval= 2MIMS_abbr_pi&product_code=311&product_name=Heparin+Sodium+ Injection. Enoxaparinsodium. http://proxy8.use.hcn.com.au/ifmx-nsapi/ mims-data/?MIval=2MIMS_abbr_pi&product_code=2658&product_name= Clexane+and+Clexane+Forte. http://www.mims.com.au.. Accessed February 2008.
2. Hirsh J, Fuster V: Guide to anticoagulant therapy. Part 1: heparin. American Heart Association. Circulation 1994, 89: 1449-1468.
3. Rich JD, Maraganore JM, Young E, et al.: Heparin resistance in acute coronary syndromes. J Thromb Thrombolysis 2007, 23: 93-100.
4. Xiao Z, Theroux P: Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 1998, 97: 251-256.
5. University of Washington Medical Center Anticoagulation Services: Guidelines for dosing and monitoring enoxaparin. http://www.uwmcacc.org/ Enoxaparin.html. Accessed February 2008.
6. Telford AM, Wilson C: Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome. Lancet 1981, 1: 1225-1228.
7. Théroux P, Ouimet H, McCans J, et al.: Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988, 319: 1105-1111.
8. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISC Group [no authors listed]. Lancet 1990, 336: 827-830.
9. NeriSerneri GG, Modesti PA, Gensini GF, et al.: Randomised comparison of subcutaneous heparin, intravenous heparin, and aspirin in unstable angina. Studio Epoorine Sottocutanea nell'Angina Instobile (SESAIR) Refrattorie Group. Lancet 1995, 345: 1201-1204. (Published erratum appears in Lancet 1995, 346: 130.)
10. Théroux P, Waters D, Qiu S, et al.: Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation 1993, 88(5 Pt 1): 2045-2048.
11. Braunwald E, Antman EM, Beasley JW, et al.: ACC/AHA 2002 Guideline Update for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Available at http://www.acc.org/qualityandscience/clinical/ guidelines/unstable/update_index.htm. Accessed February 2008.
12. Melloni C, Alexander KP, Chen AY, et al.: Unfractionated heparin dosing and major bleeding in non-ST-segment elevation acute coronary syndromes [abstract 1800]. Circulation 2007, 116: II383.
13. Théroux P, Waters D, Lam J, et al.: Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992, 327: 141-145.
14. Bijsterveld NR, Peters RJ, Murphy SA, et al.: Recurrent cardiac ischemic events early after discontinuation of short-term heparin treatment in acute coronary syndromes: results from the Thrombolysis in Myocardial Infarction (TIMI) 11B and Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) studies. J Am Coll Cardiol 2003, 42: 2083-2089.
15. Antman EM, McCabe CH, Gurfinkel EP, et al.: Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999, 100: 1593-1601.
16. Bijsterveld NR, Moons AH, Meijers JC, et al.: Rebound thrombin generation after heparin therapy in unstable angina. A randomized comparison between unfractionated and low-molecular-weight heparin. J Am Coll Cardiol 2002, 39: 811-817.
17. Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators [no authors listed]. J Am Coll Cardiol 1997, 29: 1474-1482.
18. Goodman SG, Cohen M, Bigonzi F, et al.: Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events. J Am Coll Cardiol 2000, 36: 693-698.
19. Mark DB, Cowper PA, Berkowitz SD, et al.: Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events [unstable angina or non-Q-wave myocardial infarction]. Circulation 1998, 97: 1702-1707.
20. Blazing MA, de Lemos JA, White HD, et al.: Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. A to Z Investigators. JAMA 2004, 292: 55-64. (Published erratum appears in JAMA 2004, 292: 1178.)
21. Ferguson JJ, Califf RM, Antman EM, et al.: Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. SYNERGY Trial Investigators. JAMA 2004, 292: 45-54.
22. Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC). FRISC study group [no authros listed]. Lancet 1996, 347: 561-568.
23. Klein W, Buchwald A, Hillis SE, et al.: Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC). Circulation 1997, 96: 61-68. (Published erratum appears in Circulation 1998, 97: 413.)
24. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease (FRISC). FRISC Investigators [no authors listed]. Lancet 1999, 354: 701-707. (Published erratum appears in Lancet 1999, 354: 1478.)
25. Murphy SA, Gibson CM, Morrow DA, et al.: Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. Eur Heart J 2007, 28: 2077-2086.
26. Yusuf S, Mehta SR, Chrolavicus S, et al.: Comparison of fondaparinux and enoxaparin in acute coronary syndromes. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. N Engl J Med 2006, 354: 1464-1476.
27. Mehta SR, Granger CB, Eikelboom JW, et al.: Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol 2007, 50: 1742-1751.
28. Stone GW, McLaurin BT, Cox DA, et al.: Bivalirudin for patients with acute coronary syndromes. ACUITY Investigators. N Engl J Med 2006, 355: 2203-2216.
29. Antman EM, Hand M, Armstrong PW, et al.: 2007 focused update of the ACC/ AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. Canadian Cardiovascular Society; American Academy of Family Physicians; American College of Cardiology; American Heart Association. J Am Coll Cardiol 2008, 51: 210-247.
30. Eikelboom JW, Quinlan DJ, Mehta SR, et al.: Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials. Circulation 2005, 112: 3855-3867.
31. Antman EM, Morrow DA, McCabe CH, et al.: Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. ExTRACT-TIMI 25 Investigators. N Engl J Med 2006, 354: 1477-1488.
32. Nallamothu BK, Bates ER, Hochman JS, et al.: Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab: results from the GUSTO-V trial. Eur Heart J 2005, 26: 1506-1512.
33. Sabatine MS, Morrow DA, Montalescot G, et al.: Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial. Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators. Circulation 2005, 112: 3846-3854.
34. Fox KA, Antman EM, Montalescot G, et al.: The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol 2007, 49: 2249-2255.
35. Keeley EC, Boura JA, Grines CL: Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials. Lancet 2006, 367: 579-588 (Published erratum appears in Lancet 2006, 367: 1656.)
36. Popma JJ, Berger P, Ohman EM, et al.: Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Ghest 2004, 126(3 Suppl): 576S-599S.
37. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. ESPRIT Investigators. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy. Lancet 2000, 356: 2037-2044. (Published erratum appears in Lancet 2001, 357: 1370.)
38. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 1997, 336: 1689-1696.
39. Brener SJ, Moliterno DJ, Lincoff AM, et al.: Relationship between activated clotting time and ischemic or hemorhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention. Circulation 2004, 110: 994-998.
40. Welsh RC, Gordon P, Westerhout CM, et al.: A novel enoxaparin regime for ST elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: a WEST sub-study. Catheter Cardiovasc Interv 2007, 70: 341-348.
41. Medina HM, Cheong BYC, O'Meallie L, et al.: The safety and efficacy of enoxaparin as antithrombin therapy during primary percutaneous coronary intervention for ST-elevation myocardial infarction [abstract]. Cardiovasc Reveasc Med 2007, 8: 116-154.
42. Yusuf S, Mehta SR, Chrolavicius S, et al.: Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006, 295: 1519-1530.